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Abstract
Objective
A considerable proportion of patients with rheumatoid arthritis (RA) do not have a satisfac-
tory response to biological therapies. We investigated the use of metabolomics approach to
identify biomarkers able to anticipate the response to biologics in RA patients.
Methods
Due to gender differences in metabolomic profiling, the analysis was restricted to female
patients starting etanercept as the first biological treatment and having a minimum of six
months’ follow-up. Each patient was evaluated by the same rheumatologist before and after
six months of treatment. At this time, the clinical response (good, moderate, none) was
determined according to the EUropean League Against Rheumatism (EULAR) criteria,
based on both erythrocyte sedimentation rate (EULAR-ESR) and C-reactive protein
(EULAR-CRP). Sera collected prior and after six months of etanercept were analyzed by
1H-nuclear magnetic resonance (NMR) spectroscopy in combination with multivariate data
analysis.
Results
Twenty-seven patients were enrolled: 18 had a good/moderate response and 9 were non
responders according to both EULAR-ESR and EULAR-CRP after six months of etaner-
cept. Metabolomic analysis at baseline was able to discriminate good, moderate, and non-
responders with a very good predictivity (Q2 = 0.68) and an excellent sensitivity, specificity,
and accuracy (100%). In good responders, we found an increase in isoleucine, leucine,
valine, alanine, glutamine, tyrosine, and glucose levels and a decrease in 3-hydroxybuty-
rate levels after six months of treatment with etanercept with respect to baseline.
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Conclusion
Our study confirms the potential of metabolomic analysis to predict the response to biologi-
cal agents. Changes in metabolic profiles during treatment may help elucidate their mecha-
nism of action.
Introduction
Over the last years, evidence has increased that early recognition and management of patients
with rheumatoid arthritis (RA) leads to better clinical and radiographic outcomes [1–7]. Start-
ing with COBRA trial [3,5,6], the concept of “window of opportunity” has been well recog-
nized, in which rapid suppression of disease decreases or resets the rate of joint damage for
years to come [8]. However, many patients fail to adequately respond to treatment [9,10], and
reliable biomarkers that accurately predict the response to therapy in individual patients are
necessary to help in decision-making [11]. Indeed, with the introduction of a wide spectrum of
new, generally expensive drugs, the era of “personalized medicine” for RA patients has become
an urgent necessity [12].
In this regards, the analysis of metabolomic profiling may be a tool of utmost value. Metabo-
lomics is based on the evaluation of biological fluids by analytical methods that allow describ-
ing a patient's metabolic profile without first having to identify markers of the disease [13].
Mass spectrometry (MS) and nuclear magnetic resonance (NMR) techniques, currently used to
finalize the metabolomic analysis, provide both the analytical profiles that reveal the amount of
each metabolite, and the correlations among metabolites through the multivariate statistical
analysis of spectroscopic signals [14]. The descriptors identified along these lines become the
coordinates of a new system of reference represented by metabolomic maps on which patients
and their response to therapy are located.
Metabolomics has already been applied to several disorders, including autoimmune diseases
and osteoarthritis among rheumatological conditions [15,16,17]. In this setting, metabolomic
analysis in distinct biological fluids showed the potential to discriminate patients with different
disease activity or different diseases, and to predict the prognosis or the response to treatments
[18–27]. In relation to this last point, some studies show that metabolic changes may predict
the efficacy of both traditional DMARDs, such as methotrexate (MTX) [24], and biological
agents [26] in patients with RA. At present, the Kapoor’s study [26] remains the only one eval-
uating the potential usefulness of metabolomics in patients treated with biological agents.
Given the ever-expanding use of these therapies, for whom approximately 30–40% of
patients subsequently develop an inadequate response [28–33], we decided to enrich the cur-
rent knowledge with this study. Our aim was to assess whether a 1H-NMR-based metabolomic
analysis in serum from patients with RA could predict the response to the anti-TNF fusion pro-
tein etanercept evaluated at six months.
Patients and Methods
Patients
Adult patients with a diagnosis of RA according to the 1987 revised classification criteria of the
American College of Rheumatology [34] and designated to start anti-TNF therapy were pro-
spectively enrolled from the rheumatology outpatient clinic at Sapienza University of Rome,
Italy. Due to gender differences in metabolomic profiles [35,36], the present analysis was
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restricted to female patients with active disease starting etanercept as the first biological treat-
ment and having a minimum of six months’ follow-up. Patients were given etanercept by 50 mg
subcutaneous doses once weekly while continuing to assume anti-rheumatic medications
(DMARDs and/or oral glucocorticoids) as required per the clinical judgment of the treating phy-
sician. Each patient was evaluated by the same rheumatologist at baseline before starting etaner-
cept and after six months from the onset of biological treatment. At recruitment data on
demographics, diet regimen, disease duration, co-morbidities, and concomitant treatments were
obtained by direct questioning and collected on a standardized electronic form. Clinical evalua-
tion in RA patients included: swollen and tender joint count (0–28), patient and physician global
assessment on a visual analogue scale (VAS, 0–100 mm), and Health Assessment Questionnaire
disability index (HAQ) [37]. Data including anti-citrullinated protein/peptide antibodies
(ACPA) and rheumatoid factor (RF) were obtained from the medical records. Each patient
underwent a blood drawing to appraise erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein (CRP); furthermore, sera samples were obtained and immediately stored at -80°C until the
metabolomic analysis was performed. Disease activity score (28 joint count, four variables;
DAS28) was calculated and the clinical response (good, moderate, none) was evaluated according
to the EUropean League Against Rheumatism (EULAR) criteria [38]. After six months of etaner-
cept therapy, RA patients were divided into two groups according to the clinical response: we
merged good and moderate categories as response against no response.
The study received Policlinico Umberto I Ethics Committee approval in accordance with
local requirements (prot. n. 589/14) and written informed consent was obtained from each
patient.
Metabolomic analysis
The serum samples were immediately frozen after collection and stored at -80°C. Serum sam-
ples were thawed at room temperature and 450 μL of each was added to 400 μL of 0.90% w/v
NaCl and of 20% v/v D2O (99.9 atom % of deuterium) solution. Each sample was stirred and
then centrifuged at 13000g for 10 minutes. Finally, 600 μL of the supernatant was transferred
into 5 mm NMR tube for the analysis.
2D 1H J-resolved (JRES) NMR spectra were acquired on a 500 MHz VNMRS Varian/Agi-
lent spectrometer (Agilent, Santa Clara, CA) at 25°C using a double spin echo sequence with
pre-saturation for water suppression and 16 transients per increment for a total of 32 incre-
ments. These were collected into 16 k data points using spectral widths of 8 kHz in F2 and 64
Hz in F1. Each free induction decay (FID) was Fourier transformed after a multiplication with
sine-bell window functions in both dimensions. JRES spectra were tilted by 45°, symmetrised
about F1, referenced to lactic acid at δH = 1.33 ppm and the proton-decoupled skyline projec-
tions (p-JRES) exported using Agilent VNMRJ 3.2 software. The exported p-JRES were aligned,
corrected for baseline offset and then reduced into spectral bins with widths ranging from 0.02
to 0.06 ppm by using the ACD intelligent bucketing method (1D NMRManager software,
ACD/Labs, Toronto, Canada). This method sets the bucket divisions at local minima (within
the spectra) to ensure that each resonance is in the same bin throughout all spectra. The area
within each spectral bin was integrated and, to compare the spectra, the integrals derived from
the bucketing procedure were normalized to the total integral region, following exclusion of
bins representing the residual water peak δ (4.33–5.17 ppm).
Statistical Analysis
The resulting data was used as input for univariate and multivariate analysis, including t-test
and analysis of variance (ANOVA), principal component analysis (PCA), and orthogonal
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projections to latent structures discriminant analysis (OPLS-DA). PCA and OPLS-DA were
performed using SIMCA-P + v.13.0.3 (Umetrics, Umeå, Sweden), SYSTAT v.13 software
(Systat Software Inc.) was used for the ANOVA test. Clinical data are expressed as median/
range; comparison between responders and non-responders was analyzed with the Mann-
Whitney test. A value of p<0.05 was considered to indicate a statistically significant difference.
PCA is a projection method used for exploiting the information embedded in multidimen-
sional data sets [39]. The data is reduced to a few latent variables (or principal components,
PCs) collecting the information implicit in the original variables correlation structure. The
presence of correlations between the original variables allows for the reduction of dimensional-
ity of the data set in the new space without noticeable loss of information. The extracted PCs
are each orthogonal and ordered in terms of percentage of explained variation, with the first
components collecting the ‘signal’ (correlated) portion of information, while minor compo-
nents can be considered as ‘noise’ components. Because PCs are, by construction, orthogonal
to each other, a clear-cut separation of the different and independent features characterizing
the data set is made possible. Each statistical unit is assigned a score relative to each extracted
component. The output from the PCA analysis consists of score plots, which provide an indica-
tion of the differences between the classes in terms of metabolic similarity.
OPLS-DA is a supervised pattern recognition technique, widely used in the field of metabo-
lomics to interpret large multivariate data sets describing differences between the groups under
study in a straightforward and accurate way. OPLS-DA separates the systematic variation in
the matrix X (spectroscopic data) into two parts, one linearly related (variation of interest) to
the matrix Y (the classification variables) and one orthogonally related (so-called orthogonal
variation or structured noise) to the matrix Y. The partitioning of the X-data improves the
interpretation of the model. For each OPLS-DA models, the variances related to the matrix Y
are explained by latent variables (LVs).
The influence of the original variables on the obtained model was determined by using vari-
able importance in the projection (VIP) values (VIP>1).
Metabolites responsible for the separation between classes were identified using an in-house
NMR database and Chenomx NMR suite v. 7.7 (Chenomx Inc., Alberta, Canada).
Results
The baseline demographics and disease characteristics of the patients (n = 27) are represented
in Table 1. Female patients only were included (median age 60.5 years, range 32–78).
According to EULAR-ESR or EULAR-CRP response criteria, we classified RA patients
treated with etanercept as responders (including good and moderate) and non-responders
after 6 months of treatment. The two criteria were consistent in dividing patients into 18
responders and 9 non-responders (Table 1), with some differences in the classification of good
and moderate responders.
Prediction of Response to Etanercept Therapy
To identify metabolomic signatures that could predict the response of RA patients to etaner-
cept, we applied PCA to NMR spectra of serum samples collected at baseline. PCA is an unsu-
pervised method useful to investigate interrelationship among groups through the detection of
potential clusters and outliers. By using this method, we obtained a model explaining 42% of
the solution variance with four PCs. We then applied a t-test to the component scores in order
to compare all the specific pairs of patient groups. According to both EULAR-ESR and
EULAR-CRP criteria, the results highlighted significant differences between patients who did
or did not respond to etanercept on the first PC (PC1) (p<0.0001). However, PCA did not
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provide discrimination between moderate and good responders. Fig 1A and 1B show the score
plots from PCA analysis for EULAR-ESR and EULAR-CRP response criteria, respectively.
Since several subject-related factors such as age, smoking, and dietary habits as well as con-
comitant treatments and co-morbidities are known to affect the metabolome [40], we decided
to assess whether any of these could explain the separation between RA patients responding
and non-responding to etanercept. To this purpose, the metabolic profiles and the above-men-
tioned factors were compared for each patient by ANOVA test (Table 2). This analysis revealed
that only co-morbidity, found in 90% of non-responders against 59% of responding patients,
affected the clustering of metabolic profiles (p = 0.041). However, by using Pearson’s simple
and partial correlation analysis to simultaneously investigate PCA score, responder or non-
responder status, and co-morbidities, we inferred that the metabolic variations on PC1 were
mainly associated with the prediction of response to etanercept. Indeed, after adjusting for co-
morbidities, the correlation coefficient between PCA score and the clinical status dropped
from 0.63 to 0.60, thus emphasizing the concept that the main driver of metabolism-based clas-
sification was represented by the condition of being responder or non-responder to biological
treatment.
Table 1. Baseline characteristics of rheumatoid arthritis patients (n = 27) by response to etanercept therapy at six months.
Good/moderate response* to etanercept
(n = 18)
No response* to etanercept
(n = 9)
Age (yrs; median/range) 60.5/32-78 62/43-70
Disease duration (months; median/range) 72/16-288 18/54-228
RF positive (n/%) 12/66.7 7/77.8
ACPA positive (n/%) 11/61.1 6/66.7
DAS28-ESR (median/range) 5.19/1.26–6.41 5.3 (4.9–7.36)
DAS28-CRP (median/range) 4.56/2.27–5.73 4.65/4.36–6.58
HAQ (median/range) 0.93/0-2.6 1/0.13–1.38
Patient global assessment (VAS, 0–100 mm) (median/
range)
60/17-100 60/26-72
Physician globl assessment (VAS, 0–100 mm) (median/
range)
41.5/18-70 47/35-78
Concomitant treatment regimen (n/%)
Glucocorticoids 4/22.2 1/11.1
DMARDs 6/33.3 0
DMARDs and glucococorticoids 7/38.9 6/66.7
No immunosuppressants 1/5.5 2/22.2
Daily glucocorticoid dose** (mg; median/range) 5/2-25 5/5-25
Weekly methotrexate dose (mg; median/range) 15/7.5–15 12.5/10-15
Mediterranean diet (n/%) 18/100 9/100
Ever smokers (n/%) 6/33.3 2/22.2
*As determined by EUropean League Against Rheumatism criteria.
**Prednisone equivalent.
Ever smokers include past and current smokers.
There were no significant differences between the two groups (comparison assessed with Mann-Whitney test for independent samples).
RF: rheumatoid factor; ACPA: anti-citrullinated protein/peptide antibodies; DAS28: disease activity score based on 28 joint counts; CRP: C-reactive
protein; ESR: erythrocyte sedimentation rate; DMARDs: disease-modifying anti-rheumatic drugs [include for responders and non responders, respectively:
methotrexate (10 and 4), sulfasalazine (1 and 0), hydroxychloroquine (3 and 0), cyclosporine (1 each), leflunomide (0 and 1]; HAQ: Health Assessment
Questionnaire; VAS: visual analogue scale.
doi:10.1371/journal.pone.0138537.t001
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Fig 1. 1H-NMRmetabolomic fingerprinting of RA patients before treatment with etanercept. (A) score plot from PCA analysis according to
EULAR-ESR; (B) score plot from PCA analysis according to EULAR-CRP; for A and B white circles represent good responders, gray circles represent
moderate responders, black circles represent non-responders. (C) score plot from OPLS-DA separating responder and non-responder patients according to
both EULAR-ESR and EULAR-CRP criteria. White circles represent responders (good and moderate) and black circles represent non-responders. (D) score
plot from OPLS-DA separating good, moderate, and non-responders according to EULAR-ESR; (E) score plot from OPLS-DA separating good, moderate,
and non-responders according to EULAR-CRP criteria, respectively; for D and E white circles represent good responders, gray circles represent moderate
responders, black circles represent non-responders.
doi:10.1371/journal.pone.0138537.g001
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It is also known that some disease-related factors (ACPA and RF status, disease duration)
may influence the treatment response in patients with RA [41–44]. By using ANOVA test, we
observed that only RF could affect the response to etanercept, with RF-positive patients being less
likely to respond to treatment (Table 2). Furthermore, to analyze the association of metabolic
profiles with inflammation, we performed a correlation between the four PCA scores and the
parameters incorporated into the EULAR-CRP and EULAR-ESR responses by using ANOVA
test (Table 3). The results showed a correlation between PC3 scores and CRP levels (F = 4.812;
p = 0.038) and between PC1 scores and tender joint count (F = 7.663; p = 0.011). This last param-
eter only could affect the response to etanercept: in fact, the median tender joint count 28 (range)
was 8 (0–21) and 12 (6–25) for responder and non-responder groups, respectively.
After having observed a good natural clustering of the metabolic profiles with PCA, we decided
to analyze the data by using a supervised model, OPLS-DA.When considering two classes of
patients, i. e. responders (good and moderate) and non-responders, we obtained a robust predic-
tive model (Q2 = 0.82) with 1 predictive and 5 orthogonal LVs explaining 45% and 32% of the
total variability, respectively. The prognostic performance of the response to therapy evaluated by
leave-one-out analysis showed 100% sensitivity and specificity (S1 Table). The score plot in Fig
1C shows a clear separation between responder and non-responder patients according to both
EULAR-ESR and EULAR-CRP. Differently, when imposing the analysis of the three classes of
patients (good, moderate, and non-responders) to the model, only OPLS-DA results according to
EULAR-ESR criteria permitted the discrimination between the two groups of responders on LV2
with a good predictivity (Q2 = 0.68) and 100% sensitivity and specificity (Fig 1D and S1 Table).
OPLS-DA results according to EULAR-CRP criteria also showed a differentiation between
good and moderate responders on LV2, albeit to a lesser extent (Q2 = 0.39; 90.9% and 100%
sensitivity for good and moderate responders, respectively; 88.9% specificity) (Fig 1E and S1
Table).
Table 2. Variability of the metabolomic profiles in terms of potential confounding variables in the four principal components identified by PCA and
expressed as F-values together with the corresponding p-values (in brackets).
PRINCIPAL COMPONENTS
PC1 PC2 PC3 PC4
Age 0.296 (0.591) 0.084 (0.775) 0.102 (0.753) 1.115 (0.301)
Smoking 0.214 (0.808) 0.999 (0.383) 0.424 (0.659) 0.714 (0.500)
Dietary habits 0.969 (0.471) 0.190 (0.976) 1.792 (0.152) 0.919 (0.502)
Concomitant treatment 0.776 (0.552) 0.464 (0.762) 0.579 (0.681) 1.226 (0.329)
Co-morbidity 4.635 (0.041) 0.940 (0.341) 0.270 (0.608) 0.184 (0.672)
ACPA 2.136 (0.156) 0.016 (0.899) 0.173 (0.681) 0.417 (0.524)
RF 4.287 (0.049) 0.013 (0.909) 0.004 (0.952) 0.085 (0.773)
Disease duration 0.033 (0.857) 2.409 (0.133) 1.400 (0.248) 0.657 (0.425)
ANOVA test, significant values (p<0.05) are in bold.
Smoking, co-morbidity, ACPA and RF variables are defined as presence or absence; dietary habits variable is defined as mediterranean diet or non-
mediterranean diet; age and disease duration variables are defined as numerical values (number of months); concomitant treatment variable is defined as
four groups: glucocorticoids, DMARDs, DMARDs and glucocorticoids and no immunosuppressants.
Among subject-related and disease-related factors, co-morbidity and RF, respectively, affected the clustering of metabolic profiles in terms of a minor
likelihood of response to treatment in patients positive for either of them. However, by using Pearson’s simple and partial correlation analysis to
simultaneously investigate PCA score, responder or non-responder status, and co-morbidities, the metabolic variations on PC1 were mainly associated
with the prediction of response to etanercept.
ACPA: anti-citrullinated protein/peptide antibodies; RF: rheumatoid factor.
doi:10.1371/journal.pone.0138537.t002
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Based on OPLS-DA results according to EULAR-ESR criteria, the 1H-NMR serum metabo-
lomic profiles of responder patients exhibited higher levels of N-acetylglycoprotein, methio-
nine, pyroglutamate, glutamine, and glucose, as well as lower levels of lactate, arginine, lysine,
acetate, sarcosine, aspartate, choline, and formate with respect to non responders. Further-
more, the metabolomic profile of good responders differed from that of moderate responders
mainly in the levels of 3-hydroxybutyrate and 1-methyl-hystidine, which were significantly
higher, and in the level of alanine, which was significantly lower (Table 4).
Metabolic Response to Etanercept in Good Responders According to
EULAR-ESR Criteria
In order to further investigate the effect of etanercept treatment on the metabolomic profile of
good responders according to EULAR-ESR criteria, we applied a PCA to the dataset of serum
samples collected at baseline and after six months of treatment. This approach produced a
solution with two significant components, altogether explaining about 30% of the total variabil-
ity of the systems. A t-test was applied to these component scores in order to compare data at
baseline and after six months of treatment, which showed significant differences on PC1
(p = 0.021) (Fig 2A). Subsequently, OPLS-DA was used to identify the key discriminatory
metabolites. The model separated the metabolic profiles collected at the beginning of observa-
tion from those at the end of the experiment with 88.9% sensitivity and 77.7% specificity using
one LV (Fig 2B). Analyzing the correlation between each variable and the first LV, we observed
increased levels of isoleucine, leucine, valine, glutamine, tyrosine, and glucose and a decreased
level of 3-hydroxybutyrate after treatment.
Discussion
The main aim of this study was to evaluate the possibility of using serum metabolomic profil-
ing as a promising tool for the optimization of biological therapy in the management of RA.
Table 3. Variability of metabolomic profiles in terms of variables related to clinical and laboratory parameters in the four principal components
identified and expressed as F-values together with the corresponding p-values (in brackets).
PRINCIPAL COMPONENTS
PC1 PC2 PC3 PC4
ESR 0.133 (0.718) 0.087 (0.771) 0.993 (0.329) 0.332 (0.570)
CRP 0.709 (0.408) 0.131 (0.721) 4.812 (0.038) 0.000 (0.989)
Tender joint count 7.663 (0.011) 1.803 (0.191) 1.406 (0.247) 0.173 (0.681)
Swollen joint count 0.739 (0.398) 2.363 (0.137) 0.102 (0.753) 0.008 (0.928)
Doctor’s global VAS 0.106 (0.747) 1.637 (0.212) 0.325 (0.574) 0.215 (0.647)
Patient’s global VAS 0.519 (0.478) 0.001 (0.970) 0.000 (0.988) 1.278 (0.269)
HAQ 1.165 (0.291) 2.773 (0.108) 1.380 (0.251) 0.384 (0.541)
DAS28-ESR 1.565 (0.222) 0.330 (0.571) 0.362 (0.553) 0.015 (0.903)
DAS28-CRP 1.613 (0.216) 1.637 (0.212) 1.144 (0.295) 0.049 (0.827)
ANOVA test, significant values (p<0.05) are in bold.
The results showed a correlation between PC3 scores and CRP levels and between PC1 scores and tender joint count. This last parameter only could
affect the response to etanercept: in fact, the median tender joint count 28 (range) was 8 (0–21) and 12 (6–25) for responder and non-responder groups,
respectively.
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; VAS: visual analogue scale; HAQ: Health Assessment Questionnaire; DAS28: disease
activity score based on 28 joint counts.
doi:10.1371/journal.pone.0138537.t003
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This is a critical issue since these drugs fail to produce a response in a substantial proportion of
patients. Hence, the optimal treatment strategy should rely on a personalised approach to
Table 4. Changes in metabolites in the three groups of patients classified according to EULAR-ESR criteria (good, moderate, and non-responders)
after etanercept therapy, as determined by OPLS-DA VIP analysis.
Responders vs non-responders* Good vs moderate responders* Good responders* after six months of etanercept
Isoleucine - - ↑
Leucine - - ↑
Valine - - ↑
3-Hydroxybutyrate - ↑ ↓
Lactate ↓ - -
Alanine - ↓ -
Arginine ↓ - -
Lysine ↓ - -
Acetate ↓ - -
N-acetylglycoprotein ↑ - -
Glutamine ↑ - ↑
Methionine ↑ - -
Pyroglutamate ↑ - -
Sarcosine ↓ - -
Aspartate ↓ - -
Choline ↓ - -
Glucose ↑ - ↑
1-Methyl-hystidine - ↑ -
Tyrosine - - ↑
Formate ↓ - -
↑: increased serum levels; ↓ decreased serum levels; -: no change in serum levels.
* EULAR-ESR criteria: EUropean League Against Rheumatism criteria based on erythrocyte sedimentation rate.
doi:10.1371/journal.pone.0138537.t004
Fig 2. Etanercept caused changes in the metabolism of good responder patients according to EULAR-ESR criteria. Both unsupervised (A) (PCA)
and supervised analysis (B)(OPLS-DA) revealed a good separation between serum spectra of patients with a good response to etanercept therapy collected
at baseline (white circles) and after six months of treatment (black circles).
doi:10.1371/journal.pone.0138537.g002
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minimise periods of disease activity and patient exposure to the potential side effects of an inef-
fective and, in the case of biologics, also expensive treatment. For these reasons, biomarkers of
drug response are currently strongly desirable. Recently, Sellam and coll [45] identified a
molecular signature that could be predictive of the clinical response to rituximab, as deter-
mined by transcriptomic analysis of PBMCs from a large sample of patients with RA. Other
non invasive tools might be used to accurately predict the response to biologic drugs in patients
with RA.
In this study, we tested the metabolomic profile in a cohort of RA female patients treated
with etanercept, classified as responders (good and moderate) or non-responders according to
EULAR criteria after six months of therapy. Interestingly, our results showed significant differ-
ences in the metabolites found in baseline serum samples of patients who did or did not
respond to biological treatment. In particular, by using PCA, an unsupervised analysis, it was
possible to discriminate responders and non-responders. When using the OPLS-DA model, a
supervised analysis, even a better separation was obtained, demonstrated by an excellent pre-
diction of response to etanercept therapy with 100% sensitivity and specificity. Moreover, the
OPLS-DA model based on EULAR-ESR criteria achieved a better discrimination between good
and moderate responders with respect to the same model based on EULAR-CRP criteria,
whereas the unsupervised analysis PCA failed to find this difference. It is well known that
DAS28-ESR and DAS28-CRP scores, used to define EULAR responses, are not interchangeable
[46]. Indeed, DAS28-CRP may significantly underestimate disease activity and overestimate
the EULAR response criteria compared with DAS28-ESR [46]. Furthermore, the differences in
the mean values between the DAS28-ESR and DAS28-CRP may also be affected by patient’s
gender, yielding larger scores in females than in males by DAS28-ESR [46,47]. These observa-
tions may explain the findings in our cohort of solely female patients about the capability of
EULAR-ESR over EULAR-CRP criteria to better discriminate good and moderate responders.
Our results are consistent with those reported by Kapoor et al. in urine samples from patients
with RA and psoriatic arthritis treated with anti-TNF agents. In this study, 1H-NMR spectros-
copy revealed a frank relationship between urine metabolic profiles of RA patients at baseline
and their response to anti-TNF therapy at twelve weeks. Several metabolites contributed to this
difference, in particular histamine, xanthurenic acid, ethanolamine, and glutamine, and this
last metabolite was also increased in the serum of responders from our study. Interestingly, we
observed decreased levels of lactate in good responders with respect to non-responders, a find-
ing consistent with the observation that elevated concentrations of plasma lactate are widely
associated to inflammation [27], and with previous studies supporting lactate as a candidate
biomarker for RA severity [20].
Among the disease-related factors that may affect the response to treatment, only the RF-
negative status was associated to the response to etanercept (see PC1 in Table 2). This finding
is in agreement with the results from a large cohort of RA patients treated with anti-TNF
drugs, in whom the presence of RF or ACPA was associated with a reduced response to treat-
ment, although these antibodies only accounted for a small proportion of the variance in the
response and the majority was probably explained by genetic factors [48].
To understand whether the level of inflammation might have influenced the response to eta-
nercept, we explored the relationship between the metabolic profiles at baseline as summarized
by PCA and the parameters included in the EULAR-CRP and -ESR responses. By using the
ANOVA test, we observed a relationship between CRP and PC3 as well as between tender joint
count and PC1. However, since the principal components are orthogonal to each other, we can
derive that PC3 is independent from PC1, which was able to predict the response to treatment.
Therefore, the different metabolic fingerprints of RA patients depending on the level of inflam-
mation did not appear to be predictive of the response to etanercept. Accordingly, although
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Kapoor et al. observed a significant difference between CRP levels in patients who did or did
not respond to TNF antagonists, the partial least-squares regression analysis indicated that the
association between urine baseline metabolites and the response was independent of CRP levels
[26]. However, this topic is still controversial, as the capability of metabolomics to measure the
inflammatory status of RA has been demonstrated in a recent study, in which patients with
early arthritis were stratified by 1H-NMR metabolomics according to the levels of serum CRP
[27].
Finally, metabolomic analysis was used to identify changes in biomarkers after etanercept
treatment. Isoleucine, leucine, valine, alanine, glutamine, tyrosine, and glucose levels were
found to be increased in good responders as defined by EULAR-ESR criteria, whereas
3-hydroxybutyrate levels were reduced after treatment. Interestingly, Young et al. observed ele-
vated amounts of 3-hydroxybutyrate in RA patients, probably due to the increased lipolysis in
the swollen joints of RA patients [49–51]. Therefore, our finding of a decreased concentration
of this metabolite in RA patients supports the efficacy of etanercept treatment.
In conclusion, our study confirms the potential of metabolomic analysis to predict the
response to biologics. In spite of the limited number of patients, we were able to reproduce our
data by using both unsupervised and supervised statistical analyses and obtaining a good natu-
ral clustering of metabolomic profiles irrespective of the model applied. Moreover, with regards
to responders, this approach allowed to define the metabolic path of the patients along the
course of treatment, which may provide further insights on the mechanism of action of biologi-
cal agents. The future challenges for treating inflammation are clearly the targets to remission.
Whether or not remission might be predicted by metabolomic analysis is still unclear and it
will be the matter of a future study on a wider cohort of patients.
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